Infusion of the chemotherapeutic agent oxaliplatin leads to an acute and a chronic form of peripheral neuropathy. Acute oxaliplatin neuropathy is characterized by sensory paresthesias and muscle cramps that are notably exacerbated by cooling. Painful dysesthesias are rarely reported for acute oxaliplatin neuropathy, whereas a common symptom of chronic oxaliplatin neuropathy is pain. Here we examine the role of the sodium channel isoform Na V 1.6 in mediating the symptoms of acute oxaliplatin neuropathy. Compound and single-action potential recordings from human and mouse peripheral axons showed that cooling in the presence of oxaliplatin (30-100 μM; 90 min) induced bursts of action potentials in myelinated A, but not unmyelinated C-fibers. Whole-cell patch-clamp recordings from dissociated dorsal root ganglion (DRG) neurons revealed enhanced tetrodotoxin-sensitive resurgent and persistent current amplitudes in large, but not small, diameter DRG neurons when cooled (22°C) in the presence of oxaliplatin. In DRG neurons and peripheral myelinated axons from Scn8a med/med mice, which lack functional Na V 1.6, no effect of oxaliplatin and cooling was observed. Oxaliplatin significantly slows the rate of fast inactivation at negative potentials in heterologously expressed mNa V 1.6r in ND7 cells, an effect consistent with prolonged Na V open times and increased resurgent and persistent current in native DRG neurons. This finding suggests that Na V 1.6 plays a central role in mediating acute cooling-exacerbated symptoms following oxaliplatin, and that enhanced resurgent and persistent sodium currents may provide a general mechanistic basis for cold-aggravated symptoms of neuropathy.
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chemotherapy | peripheral nerve | abnormal axonal excitability | repetitive action potential discharge C linical use of the highly effective chemotherapeutic oxaliplatin is compromised by an acute and a chronic form of peripheral neuropathy. Acutely, 85-90% of patients exhibit muscle fasciculations (1, 2), sensory paresthesias, and occasional dysesthesias (3) , all triggered by mild cooling. Although chronic oxaliplatin-induced neuropathy has been recently linked to changes in the expression and sensitivity of transient receptor potential (TRP) channels TRPM8 and TRPA1 (4, 5) , two-pore domain potassium channels (TREK1, TRAAK) and the hyperpolarization-activated channel HCN1 (6) , the mechanism underlying acute oxaliplatin neuropathy remains unresolved. Several candidate mechanisms have been proposed including potassium channel blockade (7), calcium chelation (8) , and alterations in voltage-gated sodium channel (Na V ) kinetics (9, 10) , but none adequately account for motor and sensory symptoms nor their exacerbation by cooling.
Two tetrodotoxin (TTX)-resistant (TTX-r; Na V 1.8 and Na V 1.9) and five TTX-sensitive Na v isoforms (TTX-s; Na V 1.1, -1.2, -1.3, -1.6, -1.7) are expressed in the peripheral nervous system. Na v s generate the upstroke of the action potential (AP), but can also mediate persistent (I NaP ) and resurgent currents (I NaR ). I NaP enhances excitability around firing threshold (11, 12) and mutations augmenting I NaP have been linked to human forms of epilepsy (Na V 1.1) (13), arrhythmia (Na V 1.5) (14) , paramyotonia congenita (Na v 1.4) (15, 16) , and pain (Na v 1.7) (15, 17) . I NaR was first described in cerebellar Purkinje neurons and refers to a transient surge of inward sodium current occurring upon repolarization from a preceding period of strong depolarization (18) . Because of its unorthodox activation profile, I NaR is thought to promote burst discharge (11, 12) .
Pain associated with paroxysmal extreme pain disorder (17) and muscle cramps experienced by paramyotonia patients (16) are often exacerbated or triggered by cooling, similar to the symptoms of acute oxaliplatin neuropathy. In the peripheral nervous system, large dorsal root ganglion neurons can generate I NaP (19) and an Na V 1.6-mediated I NaR (20) . Combining single axon and patchclamp recordings, the symptoms of acute oxaliplatin neuropathy appear to be because of a temperature-sensitive enhancement of I NaR and I NaP , with Na v 1.6 strongly implicated in mediating these effects.
Results

Burst Activity in Human Myelinated Axons During Cooling and Oxaliplatin.
A direct effect on peripheral axons is likely to underlie acute oxaliplatin neuropathy. In vitro exposure of human myelinated axons to oxaliplatin (100 μM; 90 min) induced after-potentials in the A-fiber compound action potential (CAP) response to electrical stimulation at 30°C (Fig. 1A , oxaliplatin, Upper traces). Afiber after-potentials were typically discernible within 40 min and, consistent with cold-aggravated symptoms reported by patients, increased dramatically upon cooling by ∼10°C (Fig. 1A , oxaliplatin, Lower traces). Recordings of a C-fiber CAP from a human nerve fascicle that fortuitously contained very few functional Afibers remained unaffected during cooling both before and after exposure to oxaliplatin (Fig. 1B) .
Na V 1.6 Is Required for Cooling-Induced Bursts in Myelinated Axons
Following Oxaliplatin. The restriction of oxaliplatin's effect to Afibers prompted an examination of Na V 1.6, the predominant Na V isoform at adult nodes of Ranvier (21) . Similar to human fascicles, mouse sural nerve A-fiber CAP responses developed prominent after-potentials during cooling following oxaliplatin (Fig. 1C) . After-potentials were completely absent in nerves from Scn8a med/med mice lacking functional Na V 1.6 (22) and approximately halved in nerve segments from heterozygous mice (Fig. 1 D-H) . This finding implicates Na V 1.6 in the generation of stimulus-evoked burst discharge in A-fibers during cooling following oxaliplatin.
In single myelinated and unmyelinated axons, no change was observed in electrically evoked AP responses at physiological skin temperatures (∼ 30-32°C) neither in the presence nor absence of oxaliplatin ( Fig. 2A, Upper traces) . However, cooling to ∼20°C in oxaliplatin induced stimulus-evoked AP bursts in single myelinated axons ( Fig. 2A , Right, Lower traces). This effect was absent in single A-fiber recordings from Scn8a med/med mice (Fig. 2B ). Similar to CAP recordings from human C-fibers, the combination of cooling and oxaliplatin did not evoke burst responses in single murine Cfibers ( Fig. 2 C and D, and Table S1 ).
Oxaliplatin Enhances Subthreshold Excitability in Myelinated Axons.
To explore the possible excitatory role of I NaP (23) in oxaliplatininduced repetitive firing in axons, subthreshold electrical excitability was examined in mouse myelinated axons during cooling (25 ± 1°C) before and after oxaliplatin (Fig. 3) . Axonal excitability parameters sensitive to changes in membrane potential (24) were not altered by oxaliplatin (Table S2) . However, the current amplitude required to evoke a 40% CAP response during a long-lasting depolarizing current pulse was found to be reduced by oxaliplatin. This result is evident in Fig. 3 A and B as an enhancement by oxaliplatin of the sustained excitability increase during a 100-ms depolarizing current pulse (Fig. 3B) . Under control conditions, application of a depolarizing current results in an initial rapid increase in excitability (10-20 ms) that accommodates (90-100 ms, control) (Fig. 3B) . Following oxaliplatin, the degree of threshold accommodation was less pronounced, indicative of persistent sodium current activation ( Fig. 3 B and E, and Table S2 ). Consistent with the enhancement of a persistent sodium current, application of depolarizing current in the presence of oxaliplatin induced after-potentials in the A-fiber CAP response (Fig. 3C) . In contrast, hyperpolarizing the axons suppressed after-potential activity (Fig. 3D ).
Oxaliplatin and Cooling Enhance Na V 1.6-Mediated I NaR in Large DRG Neurons. In addition to I NaP , Na v 1.6 can also produce prominent I NaR . Neurons with peripheral A-fibers have large somata (25) and, consequently, sodium currents were examined in large-diameter DRG neurons (40.6 ± 4.5 μm, 48.6 ± 18.6 pF, n = 25) using wholecell patch-clamp. Under control conditions, TTX-s I NaR was observed at 30°C in DRG neurons from wild-type and, to a lesser extent, Scn8a med/med mice ( Fig. 4 A and B) . Exposure of wild-type and Scn8a med/med DRGs to oxaliplatin (30 μM) had little effect on peak I NaR at 30°C. However, at 22°C oxaliplatin produced a large I NaR in wild-type DRGs (Fig. 4B) . A smaller I NaR was also observed in DRGs from Scn8a med/med mice, but this proved to be secondary to a change in I NaP (see below and Fig. 4E) .
From the raw traces in Fig. 4 A and C, a noninactivating I NaP is evident (Fig. 4D) . To examine I NaR in isolation, I NaP determined between 400 and 475 ms was subtracted from peak I NaR . This finding revealed a prominent I NaR only in wild-type DRGs at 22°C (Fig. 4E ). This effect is not a result of variations in cell size, because I NaR was still enhanced when expressed as current density (wildtype control 22.2 ± 3.4 pA/pF at 30°C, 21.9 ± 4.9 at 22°C pA/pF, med/med mice, lacking functional Na V 1.6, show no stimulus-evoked repetitive discharge upon cooling, highlighting the importance of Na v 1.6 for cooling-induced burst discharge. n = 5; 8, P = 0.56; oxaliplatin, 29.6 ± 3.8 pA/pF at 30°C, 57.3 ± 10.6 pA/pF at 22°C, n = 5; 11, P < 0.05).
Consistent with the observations for single C-fibers in peripheral nerve (Fig. 2C ), TTX-s I NaR was not observed in small (20.3 ± 2.7 μm) DRGs under control conditions nor following oxaliplatin at 22°C (n = 12) (Fig. S1 ).
Oxaliplatin and Cooling Affect I NaP in Large DRG Neurons. The combination of oxaliplatin and cooling enhanced the magnitude of I NaP in large-diameter DRG neurons from both wild-type and Scn8a med/med mice (Fig. 4D ). The increase in I NaP seen in wildtype neurons spanned a greater voltage range and was larger in amplitude than that from Scn8a med/med DRGs. For DRG neurons from Scn8a med/med mice, the increase in I NaP under combined oxaliplatin and cooling dominated and accounts for the apparent increase in I NaR (Fig. 4 B and E, Right) .
To address the possibility that the preceding strong depolarization required to evoke I NaR might have influenced I NaP , current responses to a standard depolarizing step protocol were also examined (Fig. S2A ) and, indeed, using this protocol a comparable increase in I NaP was observed in DRGs from wild-type and Scn8a med/med mice following oxaliplatin and cooling (Fig. S2) .
Oxaliplatin Slows Fast Inactivation in Heterologously Expressed
Na V 1.6. In contrast to oxaliplatin's pronounced effects on I NaR and I NaP in DRG neurons at low temperatures, TTX-s Na V activation and steady-state fast inactivation were not affected (n = 4-10) (Fig. S3 and Table S3 ). Because several Na v isoforms med/med Right) after incubation with vehicle (black) or oxaliplatin (orange). I NaR was corrected for each individual trace by subtracting the I NaP component (D) from the peak I NaR (B). Mice ranging in age from P14-25 were used. (*P < 0.05, **P < 0.01).
contribute to sodium currents in isolated DRG neurons, the effect of oxaliplatin on Na v 1.6 was examined in isolation in neuron-derived ND7/23 cells transfected with murine Na V 1.6r and auxiliary β4-subunit. Consistent with previous reports (26) , heterologous coexpression of mNa V 1.6r and β4 failed to yield appreciable I NaR (Fig. S4) . Oxaliplatin shifted steady-state fast inactivation for mNa V 1.6r in the depolarizing direction (V half control: −65.9 ± 0.8 mV; oxaliplatin: −61.7 ± 0.7 mV; P < 0.001) but was without effect on the voltage-dependence of activation (Fig. S5) . However, oxaliplatin (30 μM) affected the rate of fast inactivation in a voltage-dependent manner, considerably slowing inactivation at negative membrane potentials (Fig. 5C) .
A voltage-dependent slowing of fast inactivation by oxaliplatin could lead to an enhanced I NaR by increasing Na V open time at negative membrane potentials following expulsion of the blocking particle (Fig. 5D, arrow 2) . This possibility was examined formally using numerical simulations in an established model of I NaR in a cerebellar Purkinje neuron (27, 28) . The model was adjusted initially (see Materials and Methods) to emulate the experimentally determined kinetics of I NaR in DRG neurons (Fig. 5E ).
Selective slowing of the inactivation rate constant (Oon) resulted in an enhanced resurgent sodium current and the induction of a persistent current component ( Fig. 5E and Discussion) comparable to that observed in DRG neurons exposed to oxaliplatin at 22°C (Fig. 5A) .
Discussion
Acute cooling-aggravated neuropathy affects the overwhelming majority (>80%) of patients receiving intravenous oxaliplatin (1, 2). Using electrophysiological recordings from human and mouse peripheral nerve, it has been possible to show that these coolingaggravated symptoms can be attributed to the induction of aberrant burst discharges in peripheral myelinated axons, with C-fibers remaining notably unaffected. Oxaliplatin slows the time course of fast inactivation in cell-expressed Na v 1.6 and, in combination with cooling, this may favor a specific enhancement of Na v 1.6-mediated I NaR and I NaP in large-diameter DRG neurons. The enhanced I NaR is further thought to underlie burst-firing in peripheral sensory and motor myelinated axons expressing Na v 1.6, and thus the symptoms of acute oxaliplatin neuropathy. Upper) or, if an appropriate blocking particle (black circle) is present, block in the open configuration (Lower). Upon partial repolarization to voltages between 0 and −60 mV, the blocking particle is expelled by permeating Na + generating a resurgent current (I NaR ). Resurgent current is terminated either by fast inactivation (arrow 2) or deactivation (not shown). In mNav1.6r, oxaliplatin slowed fast inactivation voltage dependently at potentials in the range of I NaR (C). (E) Comparison of DRG current recordings (gray) and mathematical simulations (black and red). To mimic the empirical slowing of fast inactivation by oxaliplatin (Lower gray trace), the rate constant (Oon) for the state transition from open (O) to inactivated (I6) was reduced to 2% of its original value (0.02 × Oon), resulting in an increase in the magnitude of simulated resurgent current and the emergence of a persistent current component. (*P < 0.05, **P < 0.01).
Na V 1.6 is the predominant nodal sodium channel expressed in peripheral motor and sensory myelinated axons (21, 29) , providing the primary current for AP propagation (30) . Because native Na v 1.6 can readily generate I NaR (20, 31) and I NaP (31) , an enhancement of both current components could readily account for aberrant axonal burst-firing following oxaliplatin and cooling.
I NaR is thought to be generated through dislodgment of an open-channel blocking particle from the Na V permeation pathway upon repolarization (32) (Fig. 5D) . The cytoplasmic tail of the β4-subunit has been postulated to serve as an endogenous blocking particle (33, 34) and β4 is present in both spinal motoneurons and DRG neurons (35) . Binding of the blocking particle is favored when the channel is open and inactivation is slowed. Accordingly, toxins, such as β-pompilidotoxin, that slow fast inactivation promote I NaR (36) . Similarly, oxaliplatin slowed fast inactivation in Na v 1.6, but significantly only at potentials ≤ 0 mV (Fig. 5C) . By delaying inactivation, oxaliplatin could enhance I NaR by increasing Na V 1.6 open probability (Fig. 5D, arrow 2) . Experimentally, temperature is shown to be a crucial cofactor for enhanced I NaR (Fig. 4B) . Cooling would be expected to slow inactivation in a voltage-independent manner, increasing both the likelihood and thus number of channels in the open-channel block configuration (Fig. 5D, arrow 1) , as well as prolonging channel-open times following dislodgment of the open-channel blocker (Fig. 5D, arrow  2 ). This finding is particularly relevant for myelinated axons in which inactivation (Q 10 ∼2.9) of nodal sodium current is more prominently slowed by cooling than activation (Q 10 ∼2.2) (37).
In addition to slowing fast inactivation, it is possible that oxaliplatin and cooling may further destabilize inactivation by affecting the binding affinity and kinetics of the blocking particle itself. This possibility, however, remains speculative with the intricate nature of the open-channel blocking process underlying I NaR not yet fully resolved.
An enhancement of I NaP was observed in large DRG neurons from wild-type and, to a lesser extent, Scn8a med/med mice, indicating that Na V isoforms in addition to Na V 1.6 are likely to be involved. Na v 1.2 and Na v 1.1 (38) have been previously shown to contribute to I NaP in DRG neurons (39) and, although a distinct I NaP component has not been reported for Nav1.7 and Nav1.3, it is also possible that these two sodium channel subtypes could contribute to the enhancement of I NaP .
I NaP has been proposed to result from occasional failures of regular fast inactivation (40). Oxaliplatin's impairment of fast inactivation in Na V 1.6 (Fig. 5C ) is likely to impact on I NaP , in particular during cooling, which slows overall gating kinetics. In axons, I NaP can be assessed using depolarizing threshold electrotonus responses and, despite studies in oxaliplatin-treated patients at 32°C showing little change (41), the ability to cool nerve segments in vitro revealed a facilitation of I NaP by oxaliplatin in peripheral myelinated axons in vitro (Fig. 3 B and E) .
The increased excitability of A-fibers, and not C-fibers, together with the enhancement of I NaR seen during cooling in combination with oxaliplatin, provides a general mechanistic basis for neuropathologies triggered or enhanced by cold, such as paroxysmal extreme pain disorder (17) and neuropathic pain following traumatic injury (42) or amputation (43) .
Materials and Methods
Experiments on Human and Mouse Nerve. Approval for the experimental use of human nerve (from five male patients, 57 ± 9 y of age) was granted by the Ethics Committee of the Medical Faculty of the University of Munich (348/ 00). Patients gave their written consent before surgery. The diagnosis precipitating biopsy or amputation was typically polyneuropathy of unknown etiology or peripheral vascular disease. Scn8a med mice (kindly provided by Heinz Beck, University of Bonn Medical
Center, Bonn, Germany) were used in accordance with ethical guidelines stipulated by German federal law (Tierschutzgesetz §1 and §4 Abs. 3). Since Na v 1.6 mice die around postnatal day (P) 20, mice ranging from P10-P30 were used
[killed by enflurane (P10-20) or carbon dioxide (>P20)]. I NaP and I NaR have been reported not to change after P14 in mice (44 Single-fiber recordings. An isolated section of mouse skin with its innervating Nervus saphenous was perfused with solution (see above) at 32.0 ± 0.5°C. Single APs were distinguished by consistency of spike shape and response latency. Signals were filtered (<5 kHz), amplified (Axopatch 200A; Axon), digitized (μ1401; Cambridge Electronic Design), and only a single unit per skin preparation was used. After a control period (∼30 min) at 30-32°C comprising a 5-min period of cooling (to 20°C), oxaliplatin (10-100 μM) was added for 120 min, and at 90 min a second 5-min period of cooling was applied. Excitability testing. The electrical excitability of myelinated axons was determined by tracking the stimulus current intensity required to maintain an A-fiber CAP of 40% amplitude during application of subthreshold polarizing currents or conditioning stimuli. Excitability parameters were determined in QTRAC (Hugh Bostock, University of London, United Kingdom) using the TRONDXS4 protocol with a 0.5-ms test pulse at bath temperatures between 24.5°C and 26.5°C.
Whole-Cell Patch-Clamp Recordings. Cultured DRG neurons (45) were incubated in either oxaliplatin (30 μM) or vehicle (DMSO 1% vol/vol) for 98 min ± 16 min. Neuron diameter was estimated from a digital image. Whole-cell voltageclamp recordings (EPC-10USB; HEKA) were performed 1 d after plating using glass electrodes (1-1.5 MΩ) containing: 140 mM CsF, 10 mM NaCl, 1 mM EGTA, 10 mM Hepes (pH 7.38, CsOH). The external solution was tempered with an inline heater (Warner Instruments) and contained: 140 mM NaCl, 3 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 5 mM D-glucose, 10 mM Hepes, 20 mM TEA-Cl, 0.1 mM CdCl 2 (pH 7.38, NaOH). For I-V curves and steady-state fast inactivation, sodium was reduced to 10 mM externally (substituted with choline) and to 2 mM internally. Series resistance was compensated to 2.7 ± 0.4 MΩ. P/4 leak correction was applied. TTX-s currents were determined by subtraction following TTX (0.5-1 μM).
Voltage protocols (0.2 Hz) were applied from either −120 mV (I NaR and I NaP ) or −90 mV (I-V and fast inactivation). For protocols, see Figs. 4 and 5. Peak I NaR was determined during the first 50 ms following step back; I NaP refers to the mean current over the 400-to 475-ms period. Half-maximum voltage (V half ) and slope (k) of activation and inactivation were determined from Boltzmann fits.
A double-exponential fit was used to determine rise (τ1) and decay (τ2) time constants from resurgent current traces (Fig. 5A) . The fit was restricted in the time domain to a period either 20 ms (−80 mV and −70 mV) or 40 ms (potentials > −70 mV) after repolarization from the prepulse. mNa V 1.6 (46) was mutated to the TTX-r variant (mNa V 1.6r, Y371S, QuikChange II XL; Agilent Technologies) and cotransfected with mβ4-GFP (47) into neuroblastoma ND7 cells. Whole-cell patch-clamp recordings (pClamp, Digidata 1322A; Axon) were performed at room temperature using the following solutions: bath: 145 mM NaCl, 4 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM D-Glucose, 10 mM Hepes, 10 mM TEA, 0.001 mM TTX, pH 7.4 (NaOH); pipette: 125 mM CsCl, 5 mM NaCl, 2 mM Mg 2 ATP, 10 mM Hepes, 5 mM EGTA (pH 7.2, CsOH). Cells were incubated with oxaliplatin (30 μM, >30 min). Fast inactivation time constants were determined from activation protocols using single exponential fits over the 4.45-ms period following the peak current.
NEURON Simulation. Simulations were performed in NEURON (48) for Na V currents in a cerebellar Purkinje neuron incorporating I NaR (27, 28) and comprising closed (C), open (O), open-channel blocked (OB), and inactivated (I) states. Initial adjustment to model parameters ε (from 1.75 to 0.02) and Ooff (from 0.005 to 0.001) were made to emulate the empirical control trace (Fig. 5E, gray traces) .
Chemicals. Drugs were added to external solutions on the day of each experiment from stock solutions; oxaliplatin (Sigma-Aldrich) was solved in DMSO and TTX in distilled water. DMSO (0.1-1% vol/vol) applied alone to each of the preparations had no detectable effect.
Statistics. Data are presented as mean ± SEM for comparisons between groups and mean ± SD for population descriptors. A two-way ANOVA with post hoc Scheffé or Student t test were used for statistical comparisons.
Supporting Information
Sittl et al. 10 .1073/pnas.1118058109 Fig. S1 . Mediate persistent (I NaP ) and resurgent currents (I NaR ) are not apparent in small diameter dorsal root ganglion (DRG) neurons and are not affected by oxaliplatin. Representative whole-cell currents in response to a series of voltage commands (Upper) from small diameter (20.3 + 0.8 μm, n = 12) DRG neurons from wild-type mice after incubation with vehicle or oxaliplatin (30 μM, ∼90 min). Neither tetrodotoxin-sensitive (TTX-s) I NaR nor I NaP were observed in any of the 12 neurons following vehicle or oxaliplatin. Postnatal day (P) 14-25 mice were used. To assess sodium current activation, large-diameter DRG neurons from wild-type mice were held at −90 mV and depolarized in 10-mV increments up to +10 mV. To improve voltage clamp, external sodium was reduced to 10 mM (see current traces in A) . Conductances were determined as detailed in Materials and Methods and normalized to the maximum conductance. (C) Steady-state fast inactivation was assessed using a brief test pulse to +0 mV applied at the end of a 500-ms prepulse at voltages between −140 and +0 mV (C, Inset). Peak inward current was normalized to the maximum current. Fig. S4 . Resurgent current was not observed in ND7 cells cotransfected with mNav1.6r and β4-subunit and exposed to oxaliplatin. Representative current recordings from one of 11 ND7 cells cotransfected with mNav1.6r and β4-subunit following incubation with oxaliplatin (30 μM, 90 min). Fig. S5 . Oxaliplatin produces a depolarizing shift of steady-state fast inactivation for mNav1.6r cotransfected with β4 subunit in ND7 cells. Voltage-dependence of activation (g-V curve) and steady-state fast inactivation (control: black symbols, n = 31; oxaliplatin 30 μM: gray markers, n = 25) in ND7 cells cotransfected with mNav1.6r and β4 subunit. Activation was assessed using the step protocol shown in in Fig. 5C , Inset. Conductance was calculated as outlined in Materials and Methods. A 1-s prepulse followed by a test pulse to 0 mV was used to assess steady-state fast inactivation. Recordings were performed at room temperature (∼22°C). (***P < 0.001). Threshold electrotonus (TE) parameters were determined using polarizing currents set to ± 40% of the unconditioned threshold. Values presented as mean ± SEM, n = 9; age: 122-194 d (163.8 ± 63.9 d); weight: 24.4-34.0 g (27.9 ± 3.1 g). Recording temperature: 25.5 ± 1°C. CAP, compound action potential. 
